Key result
Bicyclol significantly alleviated fasting blood glucose, insulin resistance, and hepatic lipid accumulation in rats with T2DM and NAFLD by inhibiting inflammation and suppressing the Akt/PGC-1α/PEPCK signaling pathway.
Why the study?
Chronic liver inflammation underlies combined T2DM and NAFLD, making it essential to identify safe and effective agents that inhibit liver inflammation to improve glucose metabolism disorders.
Does bicyclol improve glucose metabolism and liver inflammation in a rat model of T2DM-NAFLD?
Does bicyclol improve glucose metabolism and liver inflammation in a rat model of T2DM-NAFLD?
Bicyclol improves glucose metabolism and reduces liver inflammation in a rat model of T2DM-NAFLD by regulating the Akt/PGC-1α/PEPCK signaling pathway.
Targeting liver inflammation may improve glucose metabolism in T2DM-NAFLD; leaves open clinical translation from Level 5 evidence.
Hepatic gluconeogenesis plays an important role in maintaining the body's glucose metabolism homeostasis. Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver diseases, when combined with type 2 diabetes mellitus (T2DM), it can cause severe glucose metabolism disorders. Studies have confirmed that chronic liver inflammatory lesions are the basis of T2DM combined with NAFLD (T2DM-NAFLD), inhibiting liver inflammation can improve glucose metabolism disorders. It is essential to explore safe and effective drugs to inhibit liver inflammation to improve the body's glucose metabolism disorders. Bicyclol is a biphenyl derivative that has anti-oxidative and anti-inflammatory properties. In the present study, the hepatoprotective effects and underlying mechanisms of bicyclol in T2DM-NAFLD were investigated, and T2DM-NAFLD with/without bicyclol treatment models were established. The results revealed that bicyclol alleviated fasting blood glucose, serum transaminase levels, insulin resistance, hepatic adipogenesis, lipid accumulation and markedly reduced T2DM-NAFLD rat histological alterations of livers. Not only that, bicyclol markedly attenuated T2DM-NAFLD induced production of inflammation factors (IL-1β and TNF-α). Moreover, bicyclol suppressed the expression of insulin/gluconeogenesis signaling pathway (Akt, PGC-1α and PEPCK). These findings suggested that bicyclol might be a potentially effective drug for the treatment of T2DM-NAFLD and other metabolic disorders.
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) studied Type 2 Diabetes and Non-alcoholic Fatty Liver Disease (n=37). Bicyclol vs. Purified water (Model group) was evaluated on Fasting blood glucose, insulin resistance, and hepatic gluconeogenesis markers (p=<0.05). Bicyclol significantly alleviated fasting blood glucose, insulin resistance, and hepatic lipid accumulation in rats with T2DM and NAFLD by inhibiting inflammation and suppressing the Akt/PGC-1α/PEPCK signaling pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: